Sugi Predict

Sugi Predict / Compounds / SCHEMBL22608941

SCHEMBL22608941

SCHEMBL22608941

CC(C)(C)OC(=O)N1OCC[C@H]1c1cc(F)cc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 7/20 0.44
▸ DPP4 P27487 1/20 0.37
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ HDAC5 Q9UQL6 1/20 0.37
▸ USP2 O75604 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ GPR119 Q8TDV5 2/20 0.34
▸ USP30 Q70CQ3 1/20 0.34
▸ DDB1 Q16531 1/20 0.33
▸ CRBN Q96SW2 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18921398 1.00 RIPK1 (0.44) RIPK1DPP4HDAC1HDAC6HDAC5
SCHEMBL27054183 0.92 RIPK1 (0.39) RIPK1DPP4HDAC1HDAC6HDAC5
SCHEMBL30678267 0.92 RIPK1 (0.39) RIPK1DPP4HDAC1HDAC6HDAC5
SCHEMBL25559548 0.89 RIPK1 (0.52) RIPK1GPR119
SCHEMBL31038216 0.89 RIPK1 (0.52) RIPK1GPR119
Hydrochloric Acid SCHEMBL30338587 0.88 RIPK1 (0.38) RIPK1DPP4HDAC1HDAC6HDAC5
SCHEMBL29641499 0.88 RIPK1 (0.54) RIPK1KDM4EGPR119
SCHEMBL22232775 0.88 RIPK1 (0.54) RIPK1KDM4EGPR119
SCHEMBL29641347 0.88 RIPK1 (0.54) RIPK1KDM4EGPR119
SCHEMBL22232784 0.88 RIPK1 (0.54) RIPK1KDM4EGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4430037-B1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORP (US) 2025-10-29 — — EP disclosed
US-20250122186-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORP (US) 2025-04-17 — — US disclosed
EP-4430037-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2024-09-18 — — EP disclosed
CN-118510775-A Isoxazolidines as RIPK1 inhibitors and their use 建新公司 2024-08-16 — — CN disclosed
US-20240109882-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORP (US) 2024-04-04 — — US disclosed
US-11897876-B2 Isoxazolidines as RIPK1 inhibitors and use thereof GENZYME CORPORATION (US) 2024-02-13 — — US disclosed
CN-116854678-B RIPK1 inhibitors 上海齐鲁制药研究中心有限公司 2024-01-26 — — CN disclosed
CN-116854678-A RIPK1 inhibitors 上海齐鲁制药研究中心有限公司 2023-10-10 — — CN disclosed
CN-116547281-A Isoxazolidines as RIPK1 inhibitors and uses thereof 赛诺菲 2023-08-04 — — CN disclosed
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-07-13 — — US disclosed
US-20230203027-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION 2023-06-29 — — US disclosed
US-20230192676-A1 Heterocyclic Amides as Kinase Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-06-22 — — US disclosed
US-20230192676-A1 Heterocyclic Amides as Kinase Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-06-22 — — US disclosed
US-20230192676-A1 Heterocyclic Amides as Kinase Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-06-22 — — US disclosed
WO-2023083847-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-05-19 — — WO disclosed
WO-2023083847-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF SANOFI (FR) 2023-05-19 — — WO disclosed
EP-3732176-A1 HETEROCYCLIC AMIDES AS KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2020-11-04 — — EP disclosed
CN-111741957-A Heterocyclic amides as kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2020-10-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203027-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK2, RIPK3 RIPK1 1/4885DPP4 1596/4885HDAC1 1446/4885
US-20230192676-A1 Heterocyclic Amides as Kinase Inhibitors MAP3K19, MAP3K20, MAP3K1 RIPK1 416/4885DPP4 3048/4885HDAC1 214/4885
US-20240109882-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK2, RIPK3 RIPK1 1/4885DPP4 1596/4885HDAC1 1446/4885
US-11897876-B2 Isoxazolidines as RIPK1 inhibitors and use thereof RIPK1, RIPK2, RIPK3 RIPK1 1/4885DPP4 1596/4885HDAC1 1446/4885
US-20250122186-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK2, RIPK3 RIPK1 1/4885DPP4 1596/4885HDAC1 1446/4885
US-20230219937-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF RIPK1, RIPK4, RIPK2 RIPK1 1/4885DPP4 2271/4885HDAC1 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.